CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

Officially Launches Next-Generation MyCardia AT Cardiac Monitor

CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.

CB Scientific, Inc. (CBSC) and Shenzhen Pump Medical Co., Ltd. Announce Cooperative Manufacturing Agreement for Chinese Market

Shenzhen Pump Medical Co. Ltd. to formally become the recognized manufacturer of record for CBSC's myCam device, cloud-based software, and smartphone app in China.

How can we help you?

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.